NDAORALFOR SUSPENSION
Approved
Jun 2013
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZEGERID OTC is an over-the-counter oral suspension combining omeprazole (a proton pump inhibitor) with sodium bicarbonate to provide rapid acid neutralization and sustained gastric acid suppression. It is indicated for the treatment of frequent heartburn and acid reflux in adults. The sodium bicarbonate component allows faster onset of action compared to omeprazole alone by immediately neutralizing stomach acid.
Peak
Product is at peak lifecycle stage in the competitive OTC antacid market with moderate competitive pressure (30%), suggesting stable but not expanding commercial teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ZEGERID OTC offers exposure to OTC brand management and consumer marketing strategy in a competitive, mature market segment. Career growth depends on maintaining market share against generics and branded competitors rather than driving expansion into new indications.
Brand ManagerOTC Marketing Manager
Worked on ZEGERID OTC at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.